Elderly patients treated with tinzaparin (Innohep®) administered once daily (175 anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 800-804

  Siguret, V ^a   Pautas, E ^a   Fevrier, M ^a   Wipff, C ^a   Durand Gasselin, B ^a   Laurent, M ^a   Andruex, J P ^a   D'Urso, M ^a   Gaussem, P ^a  

^a HÔPITAL CHARLES FOIX   (France)

Author keywords

Elderly; Low molecular weight heparin; Pharmacokinetics; Tinzaparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CREATININE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; TINZAPARIN;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; ELDERLY CARE; FEMALE; HEMATOMA; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOEMBOLISM;

EID: 0033710044     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614119     Document Type: Article

References (18)

1. Low molecular weight heparins: Practical considerations
2. Heparin and a low molecular weight heparin
3. Adjusted versus fixed doses of the low molecular weight heparin Fragmin® in the treatment of deep vein thrombosis
4. Low molecular weight heparin therapy: Is monitoring needed?
5. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
6. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
7. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
8. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment in the treatment of deep vein thrombosis
9. A comparison of low-molecular-weight heparin for acute pulmonary embolism
10. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis
11. Heparin pharmacokinetics and pharmacodynamics
12. Aging and the kidneys
13. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)
14. Pharmacokinetic parameters of Innohep® 175 IU/kg/day in healthy volunteers and in patients with deep vein thrombosis
15. Prediction of creatinine clearance from serum creatinine
16. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238)
17. Aging and heparin-related bleeding
18. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers